focus -WSS

focus

author：entertainment 2025-09-03 03:17:40 - browse：84871

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Bird flu in milk supply is likely coming from asymptomatic cows

leisure time

WSS

Dogs on Prozac: What pet anti

Study finds gene variants tied to breast cancer risk in Black women

FDA poised to publish guidelines for clinical trial diversity

Q&A: Jennifer Adair on making gene therapy available globally

Cue Health's Covid

Making the case for fair compensation in clinical trials

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Q&A: Jennifer Adair on making gene therapy available globally

Duchenne breakthrough therapy leaves behind pioneering families

Health care needs a new profession: neuroimaging counseling

The cancer drug shortage isn’t new — and neither are the solutions

Q&A: Jennifer Adair on making gene therapy available globally

Hollywood unions extend contract negotiations for actors

Why does health care cost so much? A reading guide

After affirmative action ruling, medical educators look to 'holistic review'

Getting Alzheimer's drug Leqembi to patients can be a challenge

explore

Exact Sciences stock tumbles despite strong cancer detection sales

Close Medicare's dangerous gaps in addiction treatment coverage

H5N1 bird flu outbreak: Second human case reported, in Michigan

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Element Biosciences CEO lays out genome sequencing strategy

Fentanyl is making it harder to start addiction treatment

Wikipedia

Wikipedia

leisure time

focus